

News Releases

All Years

Search

Go

[Advanced Search](#)

FEB 28, 2024

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

JAN 23, 2024

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to \$2.2B

NOV 9, 2023

Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

NOV 2, 2023

Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

OCT 18, 2023

Inhibrx Announces Participation in Upcoming Scientific Conferences

SEP 19, 2023

Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada

AUG 29, 2023

Inhibrx Announces \$200 Million Private Placement Financing

AUG 7, 2023

Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

MAY 30, 2023

Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

MAY 8, 2023

Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

APR 26, 2023

Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials

MAR 6, 2023

Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results

JAN 4, 2023

NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates

NOV 18, 2022

Inhibrx Announces Participation in Upcoming Investor Conference

NOV 16, 2022

Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma

NOV 7, 2022

Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

OCT 20, 2022

Inhibrx Announces Participation in Upcoming Scientific Conferences

OCT 4, 2022

Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study

OCT 3, 2022

Inhibrx To Host Webcast to Announce Regulatory Pathway for INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

AUG 15, 2022

European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma

AUG 8, 2022


Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

JUN 30, 2022

Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional \$60 Million from Oxford Finance

MAY 19, 2022

Inhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting



MAY 16, 2022

INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing

 [Photos \(2\)](#)

MAY 12, 2022

Inhibrx To Host Webcast Presentation of Topline Results from the Phase 1 Trial of INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

MAY 9, 2022

Inhibrx Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

APR 25, 2022

Inhibrx Announces Formation of Scientific Advisory Board for INBRX-101

APR 5, 2022

Inhibrx to Present INBRX-101 Data at ATS 2022 Annual

Meeting

MAR 24, 2022

Inhibrx Announces Details of Presentations at 2022 AACR Annual Meeting

MAR 3, 2022

Inhibrx Receives FDA Orphan-Drug Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

FEB 28, 2022

Inhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Recent Corporate Highlights

FEB 22, 2022

Inhibrx Announces Amended Loan Agreement with Oxford

JAN 4, 2022

Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data

DEC 1, 2021

Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma

NOV 9, 2021

Inhibrx Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights

NOV 3, 2021


Inhibrx Announces Presentations at SITC 2021

NOV 1, 2021

Inhibrx Announces Participation in Upcoming Scientific and Investor Conferences

OCT 28, 2021

Inhibrx Strengthens Leadership Team with Three Key Executive Hires and Announces Appointment of Kristiina Vuori, M.D., Ph.D. to its Board of Directors



OCT 12, 2021

INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates the Potential to Achieve Normal Alpha-1 Antitrypsin Levels with Monthly Dosing

 [Photos \(2\)](#)

OCT 11, 2021

Inhibrx To Host Webcast Presentation of Interim Results from the Phase 1 Trial of INBRX-101, its Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

SEP 13, 2021

Inhibrx Announces Participation in Upcoming Investor Conference

AUG 9, 2021

Inhibrx Reports Second Quarter 2021 Financial Results

JUN 21, 2021

Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study and Announces Amended Loan Agreement with Oxford

MAY 17, 2021

Inhibrx Announces Participation in Upcoming Investor Conferences

MAY 13, 2021

Inhibrx Reports First Quarter 2021 Financial Results

MAR 12, 2021

Inhibrx Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Announces Phase 1 Single Agent Dose Escalation Results for INBRX-105, a Novel Targeted 4-1BB Agonist

FEB 1, 2021

Inhibrx Announces Participation in Upcoming Investor Conference

JAN 13, 2021

Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients

JAN 5, 2021

Inhibrx Announces Phase 1 Dose Escalation Results of INBRX-106, a Novel Hexavalent OX40 Agonist

NOV 13, 2020

Inhibrx Reports Financial Results for the Third Quarter

Inhibrx Reports Financial Results for the Third Quarter 2020 and Announces Amended Loan Agreement with Oxford

Show per page

« 1 [2](#) »



<https://inhibrx.investorroom.com/news-releases?l=50>